A Phase 1 interventional study of TNP-2092 capsules and TNP-2092 placebo capsules in Hyperammonemia, sponsored by TenNor Therapeutics (Suzhou) Limited. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-25.
Sponsored by TenNor Therapeutics (Suzhou) Limited · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The aim of the study was to evaluate the tolerability and pharmacokinetic characteristics of TNP-2092 Capsules after single-dose administration in healthy subjects, and the food effect on pharmacokinetics.
This was a single-center, randomized, double-blind, placebo-controlled, dose-ascending single-dose-administration study, and a study on the food effects on pharmacokinetics. Five dose groups of 100 mg, 200 mg, 400 mg, 800 mg, and 1200 mg will be set up.
The 100 mg, 200 mg, 800 mg, and 1200 mg groups will complete the single ascending dose study, with 10 subjects randomized in each group, 8 subjects receiving TNP-2092 and 2 receiving placebo. The drug will be administered once in each group in the fasting state, and tolerability will be evaluated on D4. Subjects were sequentially enrolled into different dose groups in ascending order of dose, and only when the previous lower dose was confirmed to be safe and well tolerated could they be enrolled into the next higher dose group.
The 400 mg group will complete the single ascending dose study, food effect study and undergo the metabolic transformation evaluation. A total of 18 subjects will be enrolled in the group and randomized into Group A and Group B, with 8 subjects receiving the investigational product and 1 receiving placebo. The drugs will be administered in the fasting state and in the fed state for two cycles, with a wash-out period of 4 days. In terms of the administration sequence, Group A will first take TNP-2092 Capsules or placebo in the fasting state, and then TNP-2092 Capsules or placebo in the fed state; Group B will first take TNP-2092 Capsules or placebo in the fed state, and then TNP-2092 Capsules or placebo in the fasting state. Tolerability evaluation will be conducted on D4 and at the end of the study of food effects on pharmacokinetics (D8).
25 studies on the registry are indexed under Hyperammonemia; 3 are open to participants now.
This study's enrollment of 58 is above the median of 31 across 16 interventional studies indexed under Hyperammonemia.
Browse Hyperammonemia studies →TenNor Therapeutics (Suzhou) Limited is the lead sponsor of 9 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In single ascending dose study, participants received single oral dose of TNP-2092 capsules 100 to 1200 mg in fasted state. In food effect study, participants received single oral dose of TNP-2092 capsules 400 mg in fasted or fed state in a two-sequence, two-period crossover design.
Drug: TNP-2092 capsules
In single ascending dose study, participants received single oral dose of TNP-2092 placebo capsules in fasted state. In food effect study, participants received single oral dose of TNP-2092 placebo capsules in fasted or fed state in a two-sequence, two-period crossover design.
Drug: TNP-2092 placebo capsules
Administered orally, 100 to 1200 mg
Also known as: Rifaquizinone
Administered orally
Also known as: Placebo
Safety of TNP-2092 by Assessment of the Number of Participants With Adverse Events (AEs)
To investigate the safety and tolerability of TNP-2092 by assessment of the number of participants with AEs. An Adverse Event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.
Time frame: Up to 8 days after the first dosing.
Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf) in Single Ascending Dose Study
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
Time frame: Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration
Area Under the Plasma Concentration Versus Time Curve From 0 to the Last Measurable Concentration (AUC0-last) in Single Ascending Dose Study
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
Time frame: Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration
Maximum Observed Plasma Concentration (Cmax) of TNP-2092 in Single Ascending Dose Study
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
Time frame: Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration
Time to Maximum Plasma Concentration (Tmax) of TNP-2092 in Single Ascending Dose Study
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
Time frame: Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration
Terminal Elimination Half-life (T1/2) in Single Ascending Dose Study
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
Time frame: Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration
Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf) in Food Effect Study
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
Time frame: Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration
Area Under the Plasma Concentration Versus Time Curve From 0 to the Last Measurable Concentration (AUC0-last) in Food Effect Study
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
Time frame: Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration
Maximum Observed Plasma Concentration (Cmax) of TNP-2092 in Food Effect Study
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
Time frame: Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration
Time to Maximum Plasma Concentration (Tmax) of TNP-2092 in Food Effect Study
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
Time frame: Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration
Terminal Elimination Half-life (T1/2) in Food Effect Study
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
Time frame: Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration
| Milestone | TNP-2092 Capsules 100mg (Fasting) | TNP-2092 Capsules 200mg (Fasting) | TNP-2092 Capsules 400mg - Group A (Fasting - Fed) | TNP-2092 Capsules 800mg (Fasting) | TNP-2092 Capsules 1200mg (Fasting) | Placebo (Fasting) | TNP-2092 Capsules 400mg - Group B (Fed -Fasting) | Placebo (Fed-fasting) | Placebo (Fasting-fed) |
|---|---|---|---|---|---|---|---|---|---|
| Started | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 1 | 1 |
| Completed | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 1 | 1 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
To investigate the safety and tolerability of TNP-2092 by assessment of the number of participants with AEs. An Adverse Event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.
| Participants | TNP-2092 Capsules 100mg (Fasting) | TNP-2092 Capsules 200mg (Fasting) | TNP-2092 Capsules 400mg (Fasting ) | TNP-2092 Capsules 800mg (Fasting) | TNP-2092 Capsules 1200mg (Fasting) | Placebo (Fasting) | TNP-2092 Capsules 400mg - (Fed) | Placebo (Fed) |
|---|---|---|---|---|---|---|---|---|
| Safety of TNP-2092 by Assessment of the Number of Participants With Adverse Events (AEs) | 0 | 1 | 2 | 1 | 1 | 1 | 2 | 0 |
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
| h*µg/L | TNP-2092 Capsules 100mg (Fasting) | TNP-2092 Capsules 200mg (Fasting) | TNP-2092 Capsules 400mg Group A (Fasting) | TNP-2092 Capsules 800mg (Fasting) | TNP-2092 Capsules 1200mg (Fasting) |
|---|---|---|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf) in Single Ascending Dose Study | 67.9 ± 29.9 | 164 ± 65.7 | 201 ± 71.4 | 408 ± 480 | 339 ± 176 |
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
| h*µg/L | TNP-2092 Capsules 100mg (Fasting) | TNP-2092 Capsules 200mg (Fasting) | TNP-2092 Capsules 400mg Group A (Fasting) | TNP-2092 Capsules 800mg (Fasting) | TNP-2092 Capsules 1200mg (Fasting) |
|---|---|---|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve From 0 to the Last Measurable Concentration (AUC0-last) in Single Ascending Dose Study | 65.4 ± 28.8 | 161 ± 65.0 | 197 ± 71.0 | 404 ± 478 | 335 ± 175 |
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
| µg/L | TNP-2092 Capsules 100mg (Fasting) | TNP-2092 Capsules 200mg (Fasting) | TNP-2092 Capsules 400mg Group A (Fasting) | TNP-2092 Capsules 800mg (Fasting) | TNP-2092 Capsules 1200mg (Fasting) |
|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of TNP-2092 in Single Ascending Dose Study | 16.7 ± 7.80 | 41.7 ± 17.9 | 48.5 ± 20.8 | 97.4 ± 117 | 70.3 ± 41.2 |
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
| h | TNP-2092 Capsules 100mg (Fasting) | TNP-2092 Capsules 200mg (Fasting) | TNP-2092 Capsules 400mg Group A (Fasting) | TNP-2092 Capsules 800mg (Fasting) | TNP-2092 Capsules 1200mg (Fasting) |
|---|---|---|---|---|---|
| Time to Maximum Plasma Concentration (Tmax) of TNP-2092 in Single Ascending Dose Study | 3.76 ± 0.46 | 3.50 ± 0.53 | 3.50 ± 1.20 | 3.75 ± 1.04 | 3.25 ± 1.17 |
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
| h | TNP-2092 Capsules 100mg (Fasting) | TNP-2092 Capsules 200mg (Fasting) | TNP-2092 Capsules 400mg Group A (Fasting) | TNP-2092 Capsules 800mg (Fasting) | TNP-2092 Capsules 1200mg (Fasting) |
|---|---|---|---|---|---|
| Terminal Elimination Half-life (T1/2) in Single Ascending Dose Study | 2.348 ± 1.0494 | 2.778 ± 1.1949 | 2.553 ± 1.2619 | 2.819 ± 0.8444 | 3.278 ± 1.1161 |
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
| h*µg/L | TNP-2092 Capsules 400mg (Fasting) | TNP-2092 Capsules 400mg (Fed) |
|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf) in Food Effect Study | 214 ± 91.7 | 632 ± 349 |
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
| h*µg/L | TNP-2092 Capsules 400mg (Fasting) | TNP-2092 Capsules 400mg (Fed) |
|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve From 0 to the Last Measurable Concentration (AUC0-last) in Food Effect Study | 211 ± 90.6 | 628 ± 349 |
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
| µg/L | TNP-2092 Capsules 400mg (Fasting) | TNP-2092 Capsules 400mg (Fed) |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of TNP-2092 in Food Effect Study | 50.2 ± 25.2 | 102 ± 36.6 |
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
| h | TNP-2092 Capsules 400mg (Fasting) | TNP-2092 Capsules 400mg (Fed) |
|---|---|---|
| Time to Maximum Plasma Concentration (Tmax) of TNP-2092 in Food Effect Study | 3.56 ± 0.89 | 6.94 ± 2.72 |
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
| h | TNP-2092 Capsules 400mg (Fasting) | TNP-2092 Capsules 400mg (Fed) |
|---|---|---|
| Terminal Elimination Half-life (T1/2) in Food Effect Study | 2.74 ± 1.24 | 3.69 ± 0.98 |
Collected over Up to 8 days after the first dosing.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TNP-2092 Capsules 100mg (Fasting) | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
| TNP-2092 Capsules 200mg (Fasting) | 0/8 (0%) | 0/8 (0%) | 1/8 (12.5%) |
| TNP-2092 Capsules 400mg (Fasting ) | 0/16 (0%) | 0/16 (0%) | 2/16 (12.5%) |
| TNP-2092 Capsules 800mg (Fasting) | 0/8 (0%) | 0/8 (0%) | 1/8 (12.5%) |
| TNP-2092 Capsules 1200mg (Fasting) | 0/8 (0%) | 0/8 (0%) | 1/8 (12.5%) |
| Placebo (Fasting) | 0/10 (0%) | 0/10 (0%) | 1/10 (10%) |
| TNP-2092 Capsules 400mg - (Fed) | 0/16 (0%) | 0/16 (0%) | 2/16 (12.5%) |
| Placebo (Fed) | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| Event | TNP-2092 Capsules 100mg (Fasting) | TNP-2092 Capsules 200mg (Fasting) | TNP-2092 Capsules 400mg (Fasting ) | TNP-2092 Capsules 800mg (Fasting) | TNP-2092 Capsules 1200mg (Fasting) | Placebo (Fasting) | TNP-2092 Capsules 400mg - (Fed) | Placebo (Fed) |
|---|---|---|---|---|---|---|---|---|
| Activated partial thromboplastin time prolongedInvestigations | 0/8 | 0/8 | 0/16 | 0/8 | 1/8 | 0/10 | 0/16 | 0/2 |
| Blood glucose increasedInvestigations | 0/8 | 0/8 | 0/16 | 1/8 | 0/8 | 0/10 | 0/16 | 0/2 |
| DizzinessNervous system disorders | 0/8 | 1/8 | 0/16 | 0/8 | 0/8 | 0/10 | 0/16 | 0/2 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/8 | 0/8 | 0/16 | 0/8 | 0/8 | 1/10 | 0/16 | 0/2 |
| Blood bilirubin increasedInvestigations | 0/8 | 0/8 | 0/16 | 0/8 | 0/8 | 0/10 | 1/16 | 0/2 |
| Blood bilirubin unconjugated increasedInvestigations | 0/8 | 0/8 | 0/16 | 0/8 | 0/8 | 0/10 | 1/16 | 0/2 |
| AcarodermatitisInfections and infestations | 0/8 | 0/8 | 0/16 | 0/8 | 0/8 | 0/10 | 1/16 | 0/2 |
| Urinary tract infectionInfections and infestations | 0/8 | 0/8 | 1/16 | 0/8 | 0/8 | 0/10 | 0/16 | 0/2 |
| PruritusSkin and subcutaneous tissue disorders | 0/8 | 0/8 | 0/16 | 0/8 | 0/8 | 0/10 | 1/16 | 0/2 |
| AnaemiaBlood and lymphatic system disorders | 0/8 | 0/8 | 1/16 | 0/8 | 0/8 | 0/10 | 0/16 | 0/2 |
| Age, Categorical(Participants) | TNP-2092 Capsules 100mg (Fasting) | TNP-2092 Capsules 200mg (Fasting) | TNP-2092 Capsules 400mg - Group A (Fasting-fed) | TNP-2092 Capsules 800mg (Fasting) | TNP-2092 Capsules 1200mg (Fasting) | Placebo (Fasting) | TNP-2092 Capsules 400mg - Group B (Fed -Fasting) | Placebo (Fed-fasting) | Total |
|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 8 | 8 | 8 | 8 | 8 | 9 | 8 | 1 | 58 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | TNP-2092 Capsules 100mg (Fasting) | TNP-2092 Capsules 200mg (Fasting) | TNP-2092 Capsules 400mg - Group A (Fasting-fed) | TNP-2092 Capsules 800mg (Fasting) | TNP-2092 Capsules 1200mg (Fasting) | Placebo (Fasting) | TNP-2092 Capsules 400mg - Group B (Fed -Fasting) | Placebo (Fed-fasting) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 29.5 ± 9.07 | 33.6 ± 7.96 | 29.3 ± 5.34 | 28.9 ± 10.32 | 25.3 ± 5.85 | 28.3 ± 8.72 | 24.9 ± 5.96 | 19 ± 0 | 29.1 ± 8.04 |
| Sex: Female, Male(Participants) | TNP-2092 Capsules 100mg (Fasting) | TNP-2092 Capsules 200mg (Fasting) | TNP-2092 Capsules 400mg - Group A (Fasting-fed) | TNP-2092 Capsules 800mg (Fasting) | TNP-2092 Capsules 1200mg (Fasting) | Placebo (Fasting) | TNP-2092 Capsules 400mg - Group B (Fed -Fasting) | Placebo (Fed-fasting) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 2 | 3 | 4 | 4 | 4 | 3 | 4 | 0 | 24 |
| Male | 6 | 5 | 4 | 4 | 4 | 6 | 4 | 1 | 34 |
| Race (NIH/OMB)(Participants) | TNP-2092 Capsules 100mg (Fasting) | TNP-2092 Capsules 200mg (Fasting) | TNP-2092 Capsules 400mg - Group A (Fasting-fed) | TNP-2092 Capsules 800mg (Fasting) | TNP-2092 Capsules 1200mg (Fasting) | Placebo (Fasting) | TNP-2092 Capsules 400mg - Group B (Fed -Fasting) | Placebo (Fed-fasting) | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 8 | 8 | 8 | 8 | 8 | 9 | 8 | 1 | 58 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2016 to primary completion in Aug 2016, 1 month.
Results were first posted in Apr 2025, 8 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TNP-2092
TenNor Therapeutics (Suzhou) Limited